Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential iodized oil plus doxorubicin-eluting bead TACE vs doxorubicin-eluting bead TACE in unresectable hepatocellular carcinoma
ChiCTR2000035035Phase 3Recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Aug 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of doxorubicin in hepatocellular carcinoma (HCC) (2 arms), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Time to progression. Started Aug 2020; status: recruiting.
02
Drugs
doxorubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000035035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035035.